CURX · Curanex Pharmaceuticals Inc
$4.92
+0.30 (+6.49%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we do not expect our existing cash and cash equivalents to be sufficient to fund our operations for at least twelve months from the date of issuance of the unaudited interim financial statements included in this Quarterly Report. These conditions raise substantial doubt about our ability to continue as a going concern. There can be no assurance we will be successful in raising additional capital on favorable terms, or at all. Because these plans are not considered probable of being effectively implemented, they do not alleviate the substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.72M
Shares
1.57M
Volume · Oct 19
6745
Avg daily vol (41 sessions)
26.49K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.92
Open$4.62
Day$4.62–4.99
52W close$3.66–16.00
Avg vol 30d27K
Short int3K · 0.2% float · 1.0d
Short vol57%
DataAug 2025–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.47M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.94M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
+6%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−42%
trailing
YTD return
−26%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+38% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.20% of float · ▲ +9.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 1-yr high, broad support
Squeeze score
45
elevated · 0–100
Fundamentals
EPS growth
−467%
Y/Y
Balance sheet
$5.0M
net cash
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+38% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.20% of float · ▲ +9.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $5 · 10%
Range high $16
vs 200-day avg -22%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CURX
this stock
Curanex Pharmaceuticals Inc
|
$7.72M | — | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 19, 2026
- This year
- 11
Curanex Pharmaceuticals Inc disclosed two putative securities class actions filed in New York state court, on July 23, 2026 (Morales) and September 14, 2026 (Lovett), alleging material misstatements in its August 2025 IPO offering documents; the Company intends to defend them.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CURX | -7.3% | +11.8% | -42.3% | -2.2% | -25.7% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -5.9% | +12.7% | -50.0% | -2.7% | -38.1% |